Introduction: ENDURE (ClinicalTrials.gov identifier, NCT00856284), a multicenter,
economic analysis of ENDURE aimed to quantify the relationship between increased glycemic durability and cost-effectiveness of alogliptin in the UK clinical setting, and communicate its sustained glycemic benefit in economic terms. Electronic supplementary material The online version of this article (doi:10.1007/s13300-016-0206-7) contains supplementary material, which is available to authorized users.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that imposes major social and economic burdens on public health in the UK. In addition to the direct healthcare costs associated with managing T2DM, the societal and productivity consequences of T2DM also incur significant indirect costs. In 2010-11, it was estimated that T2DM affected 3.4 million adults in the UK, the cost of which exceeded £21.7 billion [1] . This was made up of £13 billion in indirect expenses and £8.7 billion in direct healthcare costs [1] , which account for up to 10% of all NHS expenditure [2] . Economic projections have hypothesized that the prevalence of T2DM in the UK will rise to 5.6 million adults in 2035-36, and will incur direct NHS costs exceeding £15.1 billion. The indirect costs of the morbidity and mortality associated with T2DM were also projected to rise, to £20.5
billion by 2035-36 [1] . More than 75% of NHS expenditure on T2DM is related to the costs of treating the complications of T2DM, rather than the ongoing management of the condition itself [1] . These complications include cardiovascular events, neuropathy, renal disorders, visual impairment, and amputations, many of which are avoidable consequences of suboptimal glycemic control. The National Institute for Health and Care Excellence (NICE) recommends that T2DM therapy ought to lower glycated hemoglobin A1c (HbA1c) levels to 48 mmol/mol (6.5%) [2] ; however, approximately 30% of patients fail to reach and maintain this goal [3] . Effective management of T2DM, through improvements to current treatment strategies, has the potential to reduce adverse micro-and macrovascular complications, and their associated burden.
Clinical guidelines for the management of T2DM initially advocate metformin, in combination with diet and lifestyle changes [2, 4] . However, given the progressive nature of T2DM due to declining beta cell function, long-term glycemic management is invariably associated with the requirement for therapy escalation [5, 6] . In patients suboptimally controlled on metformin monotherapy, sulfonylurea (SU) is a common second-line treatment option [2] . Whilst combination therapy with drugs of this class is associated with significant reductions in HbA1c, SUs are additionally associated with weight gain and an increased risk of hypoglycemia [7] . The risk of these adverse events is further exacerbated when secondary treatment failure progressively necessitates the addition of further oral therapies and/or insulin initiation [6] .
Inhibitors of dipeptidyl peptidase-4 (DPP-4) exert antihyperglycemic effects in T2DM, without increased risk of weight gain or hypoglycemic events [7] . Alogliptin is a selective inhibitor of DPP-4, and its antidiabetic efficacy in monotherapy and combination therapy has been established in clinical studies over 1 year [8] [9] [10] 
METHODS

Patient Population
Baseline characteristics and treatment effects were sourced from the ENDURE trial population (N = 2639) [11] . Patients were randomized to receive 12.5 mg alogliptin once daily (n = 880), 25 mg alogliptin once daily (n = 885), or 5 mg glipizide once daily (n = 874) for 104 weeks, in combination with at least 1500 mg open-label metformin once daily (or maximum tolerated dose). The model cohort was considered to be representative of UK patients who would be eligible to receive alogliptin as part of a UK treatment strategy.
Cost-Effectiveness Model
Economic analysis of ENDURE trial data was performed using the widely published and validated IMS Core Diabetes Model (CDM), a generic (non-product-specific) computer simulation model used to predict the long-term incidence of adverse events and the economic consequences of interventions in the management of T2DM [13] . Costs were adjusted for inflation (where necessary), set against 2015 using the hospital and community health services (HCHS) index compiled by the Personal Social Services
Research Unit (PSSRU) [18] . The annual cost of each regimen was input into the CDM as an annual cost encompassing both the treatment and consumables (test strips, lancets, and needles) required to administer and manage the treatment. The treatment and consumables were calculated using both the daily cost obtained from the latest Monthly Index of Medical Specialties (MIMS) [19] and daily usage guidelines for all individual drug regimens and consumables obtained from either the ENDURE study protocol [11] or daily usage guidelines from NICE [2] . Where relevant, an average cost of all relevant products was applied unless explicitly defined within the treatment arm (including metformin, alogliptin, and glipizide). Additional complication specific costs and overall utility consequences were applied on a per cycle basis based on the predicted occurrence of diabetes-related complications. All utilities and disutility rates were sourced from relevant literature of patients with T2DM (see appendix in the Supplementary Material). Modelled costs and utilities are provided in Tables S1-S8 in the  Supplementary Material. Across all analyses, CDM input data for the baseline cohort profile and treatment effect were sourced from published trial data [11] supplemented with validated patient level ENDURE data where required. The baseline profiles used are presented in Table 1 ; the treatment effects for both the overall population and subpopulation of patients with HbA1c less than 7.5% at week 104 that were input into the CDM are presented in Tables 2 and 3, respectively. Table 2 continued D from baseline to year 1 unless specified (mean - 
ScA-2
A secondary scenario analysis replicated the base case simulations using a subpopulation of patients who achieved an HbA1c of 7.5% or less at 2 years, in line with NICE guidelines [2] .
Compliance with Ethics Guidelines
This study was based on a previously conducted trial, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Base Case Analyses
The base case economic evaluation compared alogliptin (12.5 and 25 mg doses) to SU, as add-on therapies to metformin (Table 4 
Scenario Analysis (ScA)
ScA-1
A within-arm cost-effectiveness analysis was undertaken for each treatment group: SU, alogliptin 12.5 mg, and alogliptin 25 mg. In each analysis, patient baseline profiles were were driven by an increase in drug acquisition costs, but partly offset by a corresponding decrease in complication costs from fewer predicted events. The largest cost components in the analysis were attributable to the incidence of ulcer, amputation, and neuropathy. The addition of an SU to metformin was associated with an ICER of £10,398/QALY (Table 6) .
Treatment with alogliptin 12.5 mg was estimated to incur additional total costs (£3325) but gains in QALYs (0.315) and life expectancy (0.336 years). The additional total costs were driven by increased drug acquisition costs, which were partly offset by a reduction in complication costs from fewer predicted events.
The largest cost offsets in the analysis were attributable to CVD and renal disease, and the incidence of ulcer amputation and neuropathy. The addition of alogliptin 12.5 mg to metformin was associated with an ICER of £10,556/QALY (Table 6) . Treatment with alogliptin 25 mg was estimated to incur additional total costs (£3206) but gains in QALYs (0.352) and life expectancy (0.372 years).
The additional total costs were driven by increased drug acquisition costs, which were partly offset by a reduction in complication costs from fewer predicted events. The largest cost offsets in the analysis were attributable to CVD and renal disease, and the incidence of ulcer amputation and neuropathy. The addition of alogliptin 25 mg to metformin was associated with an ICER of £9108/QALY (Table 6) . alogliptin), to assess the cost-effectiveness profile of subjects who maintained a level of HbA1c at 2 years (104 weeks) of less than 7.5%.
Results of this scenario analysis were similar to the base case analysis in terms of absolute costs and health benefits, with ICERs (probability of cost-effectiveness at £30,000/QALY) of £13,326/ QALY (61.0%) and £6771/QALY (72.4%) for the comparison of SU and alogliptin 12.5 mg and 25 mg, respectively (Table 7) .
DISCUSSION
As a result of both the incidence and increasing prevalence of T2DM in the UK, the consequences of suboptimal glycemic control impose a considerable economic burden on patients and the NHS. These costs are further exacerbated when current treatment strategies lack the glycemic durability required to manage the progressive nature of the condition. When This economic evaluation of ENDURE provides further evidence supporting the cost-effectiveness of DPP-4 inhibitors as a second-line therapy for T2DM [20] . Previous analyses have indicated that, in T2DM patients who were no longer responsive to first-line metformin monotherapy, the addition of DPP-4 inhibitors was cost-effective compared to add-on SU [21] [22] [23] [24] [25] , thiazolidinediones [25, 26] , and insulin [27, 28] . The DPP-4 inhibitors investigated in these studies were either sitagliptin or saxagliptin; however, a pharmacoeconomic analysis of antidiabetic therapies in the Japanese clinical setting found that alogliptin was a more cost-effective DPP-4 inhibitor than sitagliptin [29] . The ENDURE trial and its subsequent cost-effectiveness analysis suggest that the improved efficacy of second-line alogliptin therapy translated to improved cost-effectiveness compared to SU in patients with uncontrolled T2DM.
There are several strengths and limitations associated with this study. A UK perspective was adopted for costs and cost-effectiveness settings (e.g., discount rates), which may affect whether these findings are relatable to other country settings. However, the input profiles and treatment effects from ENDURE were based on subjects from North and South America, 
CONCLUSION
The use of SU as a second-line indication for uncontrolled T2DM is associated with weight gain and hypoglycemic events [7] , the risks of which are further increased when doses are escalated to combat progressive treatment failure [6] . In comparison, the ENDURE trial showed that alogliptin, in combination with metformin, was associated with improved 12. Del Prato S, Fleck P, Wilson C, Chaudhari P.
Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain
